Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Myriad myRisk Blog

A Message From Myriad About COVID-19

In light of the public health preparedness efforts currently underway, Myriad’s top priorities are protecting the health and safety of employees, our customers, their patients, and doing what we can to support the healthcare system’s efforts around COVID-19. Myriad is prepared with internal contingencies related to COVID-19 to ensure that the patient samples received will […]Read More...

Myriad: Using RNA Testing in Variant Classification Since 2015

Author: Daphne Chen, MS CGC Variants of uncertain significance (VUS) are reported in a minority of hereditary cancer panel test results.  These VUS’s are continually evaluated through Myriad’s Variant Classification Program for potential reclassification based on new scientific publications, validated statistical algorithms, and other robust classification tools. Gene variants can impact the production and function […]Read More...

Germline Testing Criteria Clinical Scenario

A 44-year old female patient walks into your office. She has no personal history of cancer. Her mother was diagnosed with Stage II breast cancer at age 63, and a somatic test revealed no mutation in BRCA1/2. Her maternal uncle was diagnosed with metastatic prostate cancer at age 68. Does this patient meet guidelines for […]Read More...

Germline Testing Clinical Scenario

A 57 year old female patient walks into your office. She was diagnosed with Stage II breast cancer at age 53, and a somatic test revealed no mutation in BRCA1/2. Her brother was diagnosed with pancreatic cancer at age 68, and her aunt was diagnosed with breast cancer at 74. Does this patient meet guidelines […]Read More...

Germline BRCA1/2 testing as a necessary supplement to tumor BRCA1/2 testing

Stephanie Percich, MS, CGC Breast cancer is the most common malignancy diagnosed in women (excluding basal and squamous cell skin cancers), and as many as 10% of breast cancers in women are hereditary.1,2,3 The genes most commonly mutated in hereditary breast cancer are BRCA1 and BRCA2.2,4,5 One in 300 to 1 in 500 individuals in […]Read More...

Medical Oncology Clinical Scenario

Kira Laskin, MS, CGC Is this patient appropriate for genetic testing? Joanna was diagnosed with pancreatic adenocarcinoma at the beginning of the year, at age 64. By the time the diagnosis was made, she had been told that the cancer had already spread to her liver. Although Joanna remembers a distant cousin having dealt with […]Read More...

POLO Trial Summary

Stephanie Percich, MS, CGC Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer Metastatic pancreatic cancer is especially difficult to treat. Currently, the standard of care first-line treatments for pancreatic adenocarcinoma have a median progression-free survival of 6 months and less than 10% of those with pancreatic cancer survive more than 5 years after diagnosis.1 It […]Read More...

Lynch Syndrome

Over the past several years, awareness of the importance of hereditary cancer risk assessment has increased rapidly. Knowing whether a patient has an underlying genetic risk can be immensely helpful in guiding a patient’s medical management. Although the focus has been on the BRCA genes and breast cancer, Lynch syndrome poses a similar risk for […]Read More...

myRisk STAT: Faster Results for Patients with Pancreatic Cancer to Inform Treatment

Faster Results for Patients with Pancreatic Cancer to Inform Treatment BRCA1/2 and 9 other genes reported in 5-12 calendar days*†Full Myriad myRisk report in 14 calendar days or less Germline BRCA (gBRCA) is a Critical Biomarker for the Treatment of Patients with Pancreatic Cancer All patients with pancreatic cancer meet NCCN genetic testing criteria, but […]Read More...

Request A Meeting At ASCO 2019

Please fill out the form if you would like to schedule a meeting with a Myriad representative during ASCO 2019.Read More...